2025年3月28日 · UCB is a global biopharma company focused on creating value for people living with severe diseases. Learn more about how UCB delivers value for patients through its patient assistance program, treatment tracker and more.

In the U.S., our footprint spans from coast to coast, with U.S. sites focused on global clinical development in Raleigh, North Carolina; on policy in Washington, D.C.; and research supporting UCB's pipeline in Boston, Massachusetts and Seattle, Washington as well as …

At UCB, we keep people at the heart of everything we do. Patients should never feel alone or left with unanswered questions about medications they have been prescribed. We're proud to offer a variety of resources for those impacted by severe disease to …

As a global biopharma company, our approach to innovation keeps patients at the center. We use patient insights to inform our science to build solutions to deliver to patients. Learn more about UCB’s ongoing innovation efforts as we continue to find solutions to …

General contact information including UCB pharmaceuticals phone number, email, and UCBCares communications.

Meet the U.S UCB biopharmaceuticals leadership team at all U.S. UCB locations.

Through the UCB Patient Assistance Program, we provide some medications at no cost to eligible and qualified patients who are uninsured or underinsured who otherwise have no access to the UCB medicines prescribed by their physician.

2025年2月27日 · Jean-Christophe Tellier, CEO UCB says: “Our 2024 performance demonstrates that we are progressing on our path of growth for a decade+ and underlines our unwavering commitment to ensuring people with severe diseases can live the best life that they can, as free as possible from challenges of disease. We are proud to reaching more than 3.1 ...

2024年1月3日 · ZILBRYSQ ® (zilucoplan) is now commercially available by prescription in the United States and dispensed by UCB's selected exclusive specialty pharmacy PANTHERx ® Rare Pharmacy. ZILBRYSQ is FDA-approved as the first and only self-administered C5 complement inhibitor indicated for the treatment of gMG in adult patients who are anti-AChR ...

At UCB, our core belief has remained solid for more than 90 years. Everyone deserves to live the best life that they can – as free as possible from the challenges and uncertainty of disease. This belief fuels our ambition to create patient value for people living with immuno-dermatological diseases, rare conditions, rheumatic diseases, and more.